Systems and methods for patient-specific identification of neoantigens by de novo peptide sequencing for personalized immunotherapy

US20200243164A1 · Bioinformatics Solutions Inc. · priority 2019

Patent US20200243164A1 (Bioinformatics Solutions Inc., Abandoned): The present systems and workflows identify neoantigens for cancer immunotherapy by introducing deep learning to de novo peptide sequencing from tandem mass spectrometry data. The…
Patent US20200243164A1 ↗
Status Abandoned
Priority date 2019-01-30
Filed 2020-01-29
Published 2020-07-30
Assignee Bioinformatics Solutions Inc.
Claims DeepNovoAA

Abstract

The present systems and workflows identify neoantigens for cancer immunotherapy by introducing deep learning to de novo peptide sequencing from tandem mass spectrometry data. The systems and workflow allows for patient specific identification of neoantigens for personalized immunotherapy.

Why it is here

Claims the DeepNovoAA neoantigen workflow: personalised de novo sequencing of a patient’s immunopeptidome. Abandoned application.

Inventors (6)

Rui Qiao, Ngoc Hieu Tran, Lei Xin, Xin Chen (Waterloo), Baozhen Shan, Ming Li

An inventor links to an author page only where the same person is evident, never on a name alone.

Catalogued papers it cites (3)

Matched from the patent’s 9 literature citations by the rules the paper citation graph uses.

Cited by catalogued patents (1)

  • US11644470B2 Systems and methods for de novo peptide sequencing using deep learning and spectrum pairs

Cited by (17 patent families, 16 organisations)

Every family, of any applicant, that cites this one, as Google Patents lists them; an assignee is given its English name.

Seen in the charts

Back to the full map

Back to top